|Articles|October 25, 2005

Pharmaceutical Executive

  • Pharmaceutical Executive-10-25-2005
  • Volume 0
  • Issue 0

Predicting the Success of HPV Vaccines

Will vaccines against cervical cancer be the blockbusters that Merck and GSK are predicting? Or will issues of cost-effectiveness and parental reluctance hold them back? The experts weigh in on the debate.

Articles in this issue